Welcome to our dedicated page for Alpha Teknova news (Ticker: TKNO), a resource for investors and traders seeking the latest updates and insights on Alpha Teknova stock.
Alpha Teknova, Inc. (Nasdaq: TKNO) is a producer of critical reagents for the life sciences industry, with news flow that reflects its role in supporting therapies, vaccines, molecular diagnostics, and cell therapies. Company updates often highlight performance across its Lab Essentials and Clinical Solutions product groupings, as well as developments in its manufacturing platform and collaborations.
Investors and observers following TKNO news can expect regular earnings announcements and related commentary on revenue trends, gross margin, operating expenses, and non-GAAP metrics such as Adjusted EBITDA and Free Cash Flow. These updates are typically furnished through press releases and accompanying Form 8-K filings that discuss quarterly and full-year financial results and provide revenue breakdowns by Lab Essentials, Clinical Solutions, and Other categories.
Teknova’s news also includes product and partnership announcements. A notable example is its collaboration with Pluristyx, Inc. on the PluriFreeze cryopreservation system, where Teknova serves as the exclusive manufacturer and distributor in the United States and Canada. Press releases describe how this system is intended to streamline the manufacture of next-generation allogeneic cell therapies through synthetic, animal-origin-free cryopreservation and wash media.
Additional news items cover guidance for upcoming periods, descriptions of the company’s participation in investor conferences, and reminders about scheduled earnings calls and webcasts. For readers interested in how a life science reagents supplier communicates its financial performance, product evolution, and strategic collaborations, the TKNO news feed provides an ongoing record of Teknova’s public disclosures and corporate milestones.
Alpha Teknova (Nasdaq: TKNO) announced preliminary unaudited revenue for Q4 2021 of $10.0 to $10.1 million, including approximately $0.5 million from Sample Transport. Excluding this, revenue ranges from $9.5 to $9.6 million, marking a 25% increase year-over-year. Despite this growth, total revenue reflects a 1% decline compared to Q4 2020. The company will present its detailed financials around March 15, 2022, and will participate in investor conferences on March 9 and March 23, 2022.
Alpha Teknova, a key provider of critical reagents for biopharmaceuticals, will participate in the BTIG MedTech, Digital Health, Life Science, and Diagnostic Tools Conference from February 15-17, 2022. The company's President, Stephen Gunstream, and CFO, Matt Lowell, will host a virtual fireside chat on February 17 at 1:00 p.m. ET. They will discuss company highlights, market trends, and growth drivers. Teknova specializes in custom products for bioprocessing, offering high-quality reagents for applications like cell and gene therapy.
Alpha Teknova, Inc. (Nasdaq: TKNO) announced its inclusion in the Nasdaq Biotechnology Index (NBI), effective December 20, 2021. This index tracks the performance of Nasdaq-listed biotech stocks, highlighting Teknova's eligibility based on market capitalization, trading volume, and listing duration. CEO Stephen Gunstream praised the company's milestones since its IPO in June 2021, asserting that this recognition validates Teknova's efforts in advancing new therapies and diagnostics. The move is expected to enhance visibility among investors and position Teknova favorably within the biotech sector.
Teknova (Nasdaq: TKNO), based in Hollister, California, is a key player in providing reagents for biopharmaceutical development. The company will participate in two investor conferences: the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021, with a pre-recorded presentation on November 22 at 10:00 a.m. ET, and the Stephens 23rd Annual Investment Conference in Nashville, TN, from December 1 to 3, 2021, featuring a fireside chat on December 3 at 8:00 a.m. CT. Webcasts accessible on their Investor Relations page will remain available for 90 days.
Teknova reported total revenue of $9.4 million for Q3 2021, marking a 5% year-over-year increase. When excluding Sample Transport revenue, the company saw a notable 26% growth. Despite a strong cash position of $98.0 million, gross profit declined to $4.3 million with a gross margin of 45.4%, down from 56.6% in Q3 2020. Operating expenses surged to $8.2 million due to strategic hires and infrastructure investments, resulting in a net loss of $3.3 million for the quarter. Adjusted EBITDA was negative $2.7 million, contrasting significantly with a positive $2.7 million in the same period of 2020.
Teknova (Nasdaq: TKNO) has appointed Ken Gelhaus as Chief Commercial Officer and Jennifer Henry as Senior Vice President of Marketing. Gelhaus, with over 15 years of experience in life sciences, aims to build a successful sales team to drive growth. Henry, a veteran in branding, will bring a consumer-oriented approach to the company’s marketing strategy. This leadership change is expected to enhance Teknova’s capabilities in commercial operations and brand strategy, potentially accelerating growth in the life sciences sector.
Alpha Teknova, Inc. (TKNO) plans to disclose its third-quarter 2021 financial results on November 10, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET, allowing investors to access the discussion live via their website. Teknova specializes in providing essential reagents for biopharmaceutical development, focusing on agility and customization. The company’s proprietary processes cater to various applications like gene therapy and molecular diagnostics, aiming to accelerate breakthroughs in life sciences.
Teknova reported $8.3 million in total revenue for Q2 2021, marking a 38% year-over-year increase from $6 million. Revenue excluding Sample Transport medium rose 41% from the previous year. However, gross profit decreased to $3.4 million with a 40.4% margin, down from 57.4% in Q2 2020. Operating expenses surged to $5.9 million, driven by increased headcount. The net loss was $2.3 million, compared to net income last year. Teknova retains a strong cash position of $108 million, supporting long-term growth investments.
Alpha Teknova, Inc. (Nasdaq: TKNO) announced it will report its Q2 2021 financial results on August 11, 2021, after market close. A conference call will occur at 4:30 p.m. ET to discuss these results and provide a business update. Teknova specializes in critical reagents for biopharmaceutical development, including drug therapies and vaccines. The company's focus is on agility and customization, delivering GMP products across various applications like cell and gene therapy and mRNA therapeutics.
Alpha Teknova, Inc. (Nasdaq: TKNO) announced the closing of its initial public offering (IPO) on June 29, 2021, selling 6,900,000 shares at $16.00 each. The offering included 900,000 shares from underwriters' options, generating approximately $110.4 million in gross proceeds. The shares began trading on Nasdaq on June 25, 2021. Cowen and William Blair acted as joint book-running managers for the offering. Teknova specializes in critical reagents for biopharmaceutical products and aims to expedite clinical breakthroughs in life sciences.